semaglutide coronary artery disease Cardiovascular benefits of – QYRAL Semaglutide in Cardiometabolic Diseases: SELECTing

The patients who succeed through month 2 are the ones who throw everything at the problem, not the ones who try to minimize or endure without help

November 3, 2025: Trulicity Does Not Perform as Well as Competitor, New Study Finds A new study has found that people who took Trulicity had a higher risk of serious cardiovascular events and were more likely to die than people taking Ozempic

It is a triple-receptor agonist that simultaneously targets GLP-1, GIP and glucagon receptors

source: Policosanol 60% Policosanol seems to decrease cholesterol production in the liver and to increase the breakdown of LDL (low-density lipoprotein or bad) cholesterol

GLP-1 receptor agonists like semaglutide activate pathways in your brain that control not only hunger but also dopamine and serotonin signaling, which directly influence emotional regulation